The downstream effects of April’s federal rescheduling continued to accelerate on Monday. The FDA granted its first Breakthrough Therapy Designation to a pharmaceutical-grade cannabis extract for chronic pain, while California issued emergency regulations enabling roughly 1,600 state licensees to pursue DEA registration before a June deadline. Louisiana’s House advanced end-of-life access legislation, Pennsylvania’s medical programme crossed $9.1 billion in cumulative sales, and a new global report identified price compression as the defining signature of maturing cannabis markets.
The US Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, an investigational full-spectrum cannabis extract developed by VERTANICAL for chronic low back pain. The announcement follows two randomised, controlled Phase 3 trials demonstrating significant pain reduction and no evidence of dependence; in a head-to-head comparison VER-01 also outperformed opioids on pain reduction and gastrointestinal tolerability. European marketing authorisation is expected within weeks, and a US pivotal trial has been initiated with first data due in 2027 and a New Drug Application planned for 2028. The designation gives VERTANICAL more intensive FDA guidance and is designed to expedite development of promising therapies, lending clinical weight to the ongoing cannabis rescheduling process.
California’s Department of Cannabis Control issued emergency regulations on Monday allowing approximately 1,600 dual-licensed retailers and microbusinesses to separate their adult-use and medicinal licences, enabling the medicinal operation to apply independently for Schedule III DEA registration, according to The Marijuana Herald. The 60-day expedited DEA registration window, triggered by the April 23 rescheduling order, closes in late June. Operators restructuring under the emergency rules must maintain physically separate products, distinct inventory records, and separate business accounts. A public comment period runs 27–31 May. The action reflects the regulatory scramble under way as cannabis companies move to align with the new federal framework before the expedited deadline.
The Louisiana House voted on Monday to pass Senate Bill 270, clearing the way for the governor’s signature, according to The Marijuana Herald. The legislation, authored by state Senator Katrina Jackson-Andrews and previously approved by the Senate 33-2, would allow terminally ill patients to use medical cannabis while in qualifying healthcare facilities from 1 August 2026. Responsibility for acquiring, administering, and storing the cannabis rests solely with the patient or caregiver; healthcare staff may not assist. Smoking and vaping are prohibited, and the measure excludes behavioural health units, emergency departments, and outpatient services. Louisiana’s move follows a pattern of US states extending compassionate access within tightly defined therapeutic contexts.
A market report published on Monday by economist Beau Whitney and the Global Cannabis Network Collective identifies pricing compression as a predictable hallmark of cannabis market maturity across the United States, Canada, and Germany, with early evidence emerging across Europe and Latin America, according to PR Newswire. Germany shows “accelerated pricing pressure from import growth and regulatory shifts,” consistent with first-quarter data showing Canada supplied 53 per cent of the country’s medical flower imports. Whitney argues that operators who anticipate margin compression perform better than those who react after the fact. The Cannabis Stocks Tracker provides live market data.
Pennsylvania’s medical cannabis programme has exceeded $9.1 billion in cumulative sales since its February 2018 launch, according to The Marijuana Herald. The programme now supports 438,244 active patient certifications, 1,920 approved practitioners, and 192 operational dispensaries. Monthly sales have consistently exceeded $140 million in recent periods, reaching approximately $160 million in December 2025, the programme’s strongest month on record. The data also illustrate the price compression dynamic documented in Monday’s global market report: retail dry leaf prices have fallen from $14.90 per gram in early 2021 to $7.60 in early 2026, while wholesale prices declined from $10.65 to $2.85 over the same period. Pennsylvania’s legislature continues to evaluate an adult-use transition.
Watch this week for movement in the Senate on Farm Bill hemp provisions, with advocates pressing hard for a delay to the November 2026 THC product ban. Tomorrow is also the postal deadline for parties filing written notice of intent to participate in the DEA’s June 29 full-rescheduling hearing; a final rush of advocacy filings is expected.
The post Cannabis News Today — Tuesday 19 May 2026: FDA Backs Cannabis Pain Drug as Post-Rescheduling Wave Reaches States and Markets appeared first on Business of Cannabis.
Continue reading...
FDA Grants Breakthrough Therapy Designation to Cannabis-Derived Pain Treatment
The US Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, an investigational full-spectrum cannabis extract developed by VERTANICAL for chronic low back pain. The announcement follows two randomised, controlled Phase 3 trials demonstrating significant pain reduction and no evidence of dependence; in a head-to-head comparison VER-01 also outperformed opioids on pain reduction and gastrointestinal tolerability. European marketing authorisation is expected within weeks, and a US pivotal trial has been initiated with first data due in 2027 and a New Drug Application planned for 2028. The designation gives VERTANICAL more intensive FDA guidance and is designed to expedite development of promising therapies, lending clinical weight to the ongoing cannabis rescheduling process.
California Issues Emergency Rules to Help 1,600 Licensees Pursue DEA Registration
California’s Department of Cannabis Control issued emergency regulations on Monday allowing approximately 1,600 dual-licensed retailers and microbusinesses to separate their adult-use and medicinal licences, enabling the medicinal operation to apply independently for Schedule III DEA registration, according to The Marijuana Herald. The 60-day expedited DEA registration window, triggered by the April 23 rescheduling order, closes in late June. Operators restructuring under the emergency rules must maintain physically separate products, distinct inventory records, and separate business accounts. A public comment period runs 27–31 May. The action reflects the regulatory scramble under way as cannabis companies move to align with the new federal framework before the expedited deadline.
Louisiana House Passes Bill Allowing Medical Cannabis in End-of-Life Care Settings
The Louisiana House voted on Monday to pass Senate Bill 270, clearing the way for the governor’s signature, according to The Marijuana Herald. The legislation, authored by state Senator Katrina Jackson-Andrews and previously approved by the Senate 33-2, would allow terminally ill patients to use medical cannabis while in qualifying healthcare facilities from 1 August 2026. Responsibility for acquiring, administering, and storing the cannabis rests solely with the patient or caregiver; healthcare staff may not assist. Smoking and vaping are prohibited, and the measure excludes behavioural health units, emergency departments, and outpatient services. Louisiana’s move follows a pattern of US states extending compassionate access within tightly defined therapeutic contexts.
New Global Report Finds Price Compression Signals Cannabis Market Maturity
A market report published on Monday by economist Beau Whitney and the Global Cannabis Network Collective identifies pricing compression as a predictable hallmark of cannabis market maturity across the United States, Canada, and Germany, with early evidence emerging across Europe and Latin America, according to PR Newswire. Germany shows “accelerated pricing pressure from import growth and regulatory shifts,” consistent with first-quarter data showing Canada supplied 53 per cent of the country’s medical flower imports. Whitney argues that operators who anticipate margin compression perform better than those who react after the fact. The Cannabis Stocks Tracker provides live market data.
Pennsylvania Medical Cannabis Programme Surpasses $9.1 Billion in Cumulative Sales
Pennsylvania’s medical cannabis programme has exceeded $9.1 billion in cumulative sales since its February 2018 launch, according to The Marijuana Herald. The programme now supports 438,244 active patient certifications, 1,920 approved practitioners, and 192 operational dispensaries. Monthly sales have consistently exceeded $140 million in recent periods, reaching approximately $160 million in December 2025, the programme’s strongest month on record. The data also illustrate the price compression dynamic documented in Monday’s global market report: retail dry leaf prices have fallen from $14.90 per gram in early 2021 to $7.60 in early 2026, while wholesale prices declined from $10.65 to $2.85 over the same period. Pennsylvania’s legislature continues to evaluate an adult-use transition.
Watch this week for movement in the Senate on Farm Bill hemp provisions, with advocates pressing hard for a delay to the November 2026 THC product ban. Tomorrow is also the postal deadline for parties filing written notice of intent to participate in the DEA’s June 29 full-rescheduling hearing; a final rush of advocacy filings is expected.
The post Cannabis News Today — Tuesday 19 May 2026: FDA Backs Cannabis Pain Drug as Post-Rescheduling Wave Reaches States and Markets appeared first on Business of Cannabis.
Continue reading...
